MA31884B1 - Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3 - Google Patents

Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3

Info

Publication number
MA31884B1
MA31884B1 MA32778A MA32778A MA31884B1 MA 31884 B1 MA31884 B1 MA 31884B1 MA 32778 A MA32778 A MA 32778A MA 32778 A MA32778 A MA 32778A MA 31884 B1 MA31884 B1 MA 31884B1
Authority
MA
Morocco
Prior art keywords
kiase
thienopyrimidine
inhibitors
mtor kinase
pyrazolopyrimidine derivatives
Prior art date
Application number
MA32778A
Other languages
Arabic (ar)
English (en)
Inventor
Arie Zask
Joshua Aaron Kaplan
Jeroen Cunera Verheijen
Kevin Joseph Curran
David James Richard
Semiramis Ayral-Kaloustian
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MA31884B1 publication Critical patent/MA31884B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés thiénopyrimidine et pyrazolopyrimidine répondant aux formules (ia) et (iia), ou un sel pharmaceutiquement acceptable de ceux-ci, les variables des constituants étant telles que définies dans les présentes compositions comprenant les composés, ainsi que des procédés de fabrication et d'utilisation des composés.
MA32778A 2007-10-16 2010-04-16 Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3 MA31884B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98033207P 2007-10-16 2007-10-16
US2759508P 2008-02-11 2008-02-11
PCT/US2008/079940 WO2009052145A1 (fr) 2007-10-16 2008-10-15 Composés thiénopyrimidine et pyrazolopyrimidine et leur utilisation en tant que des inhibiteurs de la kinase mtor et de la kinase pi3

Publications (1)

Publication Number Publication Date
MA31884B1 true MA31884B1 (fr) 2010-12-01

Family

ID=40345078

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32778A MA31884B1 (fr) 2007-10-16 2010-04-16 Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3

Country Status (26)

Country Link
US (1) US8129371B2 (fr)
EP (1) EP2212333A1 (fr)
JP (1) JP2011500702A (fr)
KR (1) KR20100083170A (fr)
CN (1) CN101883774A (fr)
AP (1) AP2010005234A0 (fr)
AR (1) AR068898A1 (fr)
AU (1) AU2008312631A1 (fr)
BR (1) BRPI0817681A2 (fr)
CA (1) CA2702838A1 (fr)
CL (1) CL2008003061A1 (fr)
CO (1) CO6321257A2 (fr)
CR (1) CR11373A (fr)
DO (1) DOP2010000118A (fr)
EA (1) EA201000484A1 (fr)
EC (1) ECSP10010112A (fr)
IL (1) IL205109A0 (fr)
MA (1) MA31884B1 (fr)
MX (1) MX2010004260A (fr)
NI (1) NI201000060A (fr)
PA (1) PA8799101A1 (fr)
PE (1) PE20091384A1 (fr)
TN (1) TN2010000171A1 (fr)
TW (1) TW200922593A (fr)
WO (1) WO2009052145A1 (fr)
ZA (1) ZA201003430B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE456836T1 (de) * 1996-09-04 2010-02-15 Intertrust Tech Corp Zuverlässige infrastrukturhilfssysteme, verfahren und techniken für sicheren elektronischen handel, elektronische transaktionen, handelsablaufsteuerung und automatisierung, verteilte verarbeitung und rechteverwaltung
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201004963A (en) * 2008-07-03 2010-02-01 Targacept Inc Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands
US8163763B2 (en) * 2008-07-31 2012-04-24 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
PT2385832E (pt) * 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
ES2439793T3 (es) * 2009-04-17 2014-01-24 Wyeth Llc Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis
MX2011012520A (es) * 2009-05-27 2011-12-12 Hoffmann La Roche Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
EP2445346A4 (fr) * 2009-06-24 2012-12-05 Genentech Inc Composés pyrimidine fusionnés à oxo-hétérocycles, compositions et procédés d'utilisation
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US20110021515A1 (en) * 2009-07-24 2011-01-27 Takeda Pharmaceutical Company Limited Dihyrofuropyrmindine compounds
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
ES2567168T3 (es) * 2009-11-12 2016-04-20 F. Hoffmann-La Roche Ag Compuestos purina y pirazolopirimidina N7-sustituidos, composiciones y métodos de utilización
WO2011058027A2 (fr) * 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag Composés de purine n-9-substitués, compositions et procédés d'utilisation
WO2011078795A1 (fr) * 2009-12-21 2011-06-30 S*Bio Pte Ltd Purines pontées à substitution morpholino
WO2011090935A1 (fr) * 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. Composés pyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de mtor
BR112012019459A2 (pt) 2010-02-03 2017-10-17 Signal Pharm Llc identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
CA2793778A1 (fr) 2010-04-05 2011-11-13 Wyeth Llc Biomarqueurs d'un cancer favorise par la pi3k
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
WO2011159726A2 (fr) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogrammation de cellules pour leur conférer un nouveau destin
JP2013544829A (ja) * 2010-11-24 2013-12-19 エクセリクシス， インク． ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピンおよびその使用と製造方法
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
WO2012099581A1 (fr) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Composés de dihydrofuropyrimidine
CA2843887A1 (fr) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification d'un profil d'expression genique a titre de biomarqueur predictif de l'etat lkb1
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP2809673B1 (fr) * 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Molécules spirocycliques en tant qu'inhibiteurs de tyrosine kinase de bruton
CN103467482B (zh) 2012-04-10 2017-05-10 上海璎黎药业有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
CN103374021B (zh) * 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
CN104350144B (zh) 2012-05-23 2017-08-04 弗·哈夫曼-拉罗切有限公司 获得和使用内胚层和肝细胞的组合物和方法
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
CA2876689C (fr) 2012-06-13 2022-04-26 Incyte Corporation Composes tricycliques substitues utilises comme inhibiteurs de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP3549940A1 (fr) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Formulations pharmaceutiques associés à 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
CA2908742C (fr) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Polytherapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer
WO2014172436A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Polythérapie comprenant un inhibiteur de kinase tor et un composé de quinazolinone substitué en 5 pour le traitement du cancer
WO2014172425A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Traitement du cancer par des dihydropyrazino-pyrazines
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
JP6441910B2 (ja) 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (fr) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières
PE20161475A1 (es) * 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
CA2976790C (fr) 2015-02-20 2024-02-27 Incyte Corporation Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
EP3368039A1 (fr) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Mutations ponctuelles dans le cancer résistant aux inhibiteurs de trk et méthodes associées
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA125026C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
UA125025C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Способи лікування дитячих ракових захворювань
MX392604B (es) 2016-05-18 2025-03-24 Array Biopharma Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo.
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
CN108358949A (zh) * 2018-03-01 2018-08-03 南京法恩化学有限公司 一种2，4-二氯噻吩并[3，2-d]嘧啶的制备方法
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
CN110850012B (zh) * 2018-08-21 2022-07-08 四川弘远药业有限公司 一种1-(2,3-二氯苯基)哌嗪盐酸盐及其有关物质的检测方法
SG11202108274SA (en) * 2019-02-06 2021-08-30 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
CN109824701B (zh) * 2019-03-26 2021-08-13 武汉工程大学 一种吡啶并噻唑类化合物及其制备方法和应用
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP3800188A1 (fr) 2019-10-02 2021-04-07 Bayer AG Pyrazolopyrimidines substituées en tant qu'inhibiteurs d'irak4
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021113479A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (fr) 2021-04-12 2024-02-21 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
CN113278015B (zh) * 2021-05-31 2022-05-13 云南大学 一种荧光探针及其制备方法和应用
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
TW202602891A (zh) * 2024-03-28 2026-01-16 大陸商勵締（杭州）醫藥科技有限公司 具有mTOR抑制活性的有機化合物及其用途
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives

Also Published As

Publication number Publication date
CA2702838A1 (fr) 2009-04-23
AU2008312631A1 (en) 2009-04-23
CL2008003061A1 (es) 2009-01-09
CO6321257A2 (es) 2011-09-20
EA201000484A1 (ru) 2010-12-30
MX2010004260A (es) 2010-04-30
WO2009052145A1 (fr) 2009-04-23
AR068898A1 (es) 2009-12-16
BRPI0817681A2 (pt) 2015-04-14
KR20100083170A (ko) 2010-07-21
NI201000060A (es) 2010-10-04
PE20091384A1 (es) 2009-09-09
DOP2010000118A (es) 2010-06-30
CR11373A (es) 2010-05-03
IL205109A0 (en) 2010-11-30
TN2010000171A1 (fr) 2011-11-11
AP2010005234A0 (en) 2010-04-30
TW200922593A (en) 2009-06-01
US8129371B2 (en) 2012-03-06
CN101883774A (zh) 2010-11-10
JP2011500702A (ja) 2011-01-06
US20090098086A1 (en) 2009-04-16
ECSP10010112A (es) 2010-08-31
ZA201003430B (en) 2011-02-23
EP2212333A1 (fr) 2010-08-04
PA8799101A1 (es) 2009-05-15

Similar Documents

Publication Publication Date Title
TN2010000171A1 (fr) Derives de thienopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor te de la kinase k13
MA32615B1 (fr) Inhibiteurs de cmet
WO2007120980A3 (fr) Composés de 2,4-pyrimidinediamine pour le traitement ou la prévention de maladies autoimmunes
ATE479687T1 (de) Kinaseinhibitoren
MA31151B1 (fr) Inhibiteurs de mapk/erk kinase
WO2006105127A8 (fr) Inhibiteurs de l'hydroxysteroide deshydrogenase
WO2006066109A3 (fr) Inhibiteurs des hydroxysteroides deshydrogenases
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
WO2006123113A3 (fr) Composes chimiques
WO2008007211A8 (fr) Composés de carboxyamide bicycliques à n-bicycloalkyle substitué
MY146989A (en) Kinase inhibitors
WO2007028135A3 (fr) Composes a base d'imidazopyridine
WO2007129195A3 (fr) 4-pyrimidine-5-amino-pyrazoles
WO2008070129A3 (fr) Compositions et procédés pour le traitement de maladie inflammatoire
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
WO2007103508A3 (fr) Ligands pour récepteurs nucléaires de nématodes et leurs utilisations
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
MA32343B1 (fr) Pyrimidyle cyclopentane hydroxylé en tant qu'inhibiteur de protéine kinase akt
DE602004010680D1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
WO2006028963A3 (fr) Composes heterocycliques substitues et leurs utilisations